Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Vaccines

  Free Subscription


03.10.2022

1 Arch Pediatr
5 BMJ
1 J Immunol
3 J Infect
1 J Infect Dis
3 J Virol
4 JAMA
2 Lancet
1 MMWR Morb Mortal Wkly Rep
1 N Engl J Med
11 PLoS One
15 Vaccine
1 Virology
1 Virus Res


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Arch Pediatr

  1. YALCIN SS, Komurluoglu A, Topac O
    Rates of childhood vaccine refusal in Turkey during 2016-2017: Regional causes and solutions.
    Arch Pediatr. 2022 Sep 24. pii: S0929-693X(22)00180.
    PubMed         Abstract available


    BMJ

  2. IACOBUCCI G
    UK childhood vaccination rates fell last year in almost all programmes, figures show.
    BMJ. 2022;378:o2353.
    PubMed        

  3. MAJEED A, Pollock K, Hodes S, Papaluca M, et al
    Implementation of covid-19 vaccination in the United Kingdom.
    BMJ. 2022;378:e070344.
    PubMed        

  4. TAYLOR L
    Covid-19: PAHO calls for Americas to reverse vaccination setbacks caused by pandemic.
    BMJ. 2022;378:o2344.
    PubMed        

  5. MAHASE E
    Parents are urged to vaccinate 2-3 year olds against flu as NHS warns of "twindemic".
    BMJ. 2022;378:o2335.
    PubMed        

  6. THIAGARAJAN K
    Why did rabies control fail in India?
    BMJ. 2022;378:o2284.
    PubMed        


    J Immunol

  7. BREZNIK JA, Huynh A, Zhang A, Bilaver L, et al
    Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination.
    J Immunol. 2022 Sep 28. pii: jimmunol.2200369. doi: 10.4049/jimmunol.2200369.
    PubMed         Abstract available


    J Infect

  8. HUANG J, Xia L, Zhao Y, Wu X, et al
    Coronavirus disease 2019 vaccination and live birth outcome after fresh embryo transfer.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00552.
    PubMed        

  9. AO G, Li A, Wang Y, Tran C, et al
    The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: a meta-analysis.
    J Infect. 2022 Sep 26. pii: S0163-4453(22)00553.
    PubMed        

  10. YIN Y, Lin J, Yuan S, Tong S, et al
    A booster shot of vaccine against SARS-CoV-2 should be rigorously promoted and implemented in China.
    J Infect. 2022 Sep 25. pii: S0163-4453(22)00546.
    PubMed        


    J Infect Dis

  11. FURUKAWA K, Kurahashi Y, Ishimaru H, Nishimura M, et al
    The number of COVID-19 vaccine doses and severe clinical outcomes in older patients infected with a SARS-CoV-2 Omicron variant.
    J Infect Dis. 2022 Sep 26. pii: 6717967. doi: 10.1093.
    PubMed        


    J Virol

  12. CHABOT S, Gimie Y, Obeid K, Kim J, et al
    Enhanced In Vitro and In Vivo Potency of a T Cell Epitope in the Ebola Virus Glycoprotein Following Amino Acid Replacement at HLA-A*02:01 Binding Positions.
    J Virol. 2022;96:e0116621.
    PubMed         Abstract available

  13. REDDY VRAP, Nazki S, Brodrick AJ, Asfor A, et al
    Evaluating the Breadth of Neutralizing Antibody Responses Elicited by Infectious Bursal Disease Virus Genogroup A1 Strains Using a Novel Chicken B-Cell Rescue System and Neutralization Assay.
    J Virol. 2022;96:e0125522.
    PubMed         Abstract available

  14. SHEN W, Wang Q, Wang Z, Liu M, et al
    Specific Monoclonal Antibodies Targeting Unique HA Epitopes Block H7N9 Influenza A Viral Replication.
    J Virol. 2022 Aug 29:e0123822. doi: 10.1128/jvi.01238.
    PubMed         Abstract available


    JAMA

  15. LIN DY, Gu Y, Xu Y, Wheeler B, et al
    Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes.
    JAMA. 2022 Sep 26. pii: 2796893. doi: 10.1001/jama.2022.17876.
    PubMed         Abstract available

  16. TENFORDE MW, Link-Gelles R, Patel MM
    Long-term Protection Associated With COVID-19 Vaccination and Prior Infection.
    JAMA. 2022 Sep 26. pii: 2796894. doi: 10.1001/jama.2022.14660.
    PubMed        

  17. KELLY JD, Leonard S, Hoggatt KJ, Boscardin WJ, et al
    Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
    JAMA. 2022 Sep 26. pii: 2796892. doi: 10.1001/jama.2022.17985.
    PubMed         Abstract available

  18. HAZRA A, Rusie L, Hedberg T, Schneider JA, et al
    Human Monkeypox Virus Infection in the Immediate Period After Receiving Modified Vaccinia Ankara Vaccine.
    JAMA. 2022 Sep 30. pii: 2797135. doi: 10.1001/jama.2022.18320.
    PubMed        


    Lancet

  19. HAMEED SS, Hall E, Grange Z, Sullivan C, et al
    Characterising adults in Scotland who are not vaccinated against COVID-19.
    Lancet. 2022;400:993-995.
    PubMed        

  20. ZIEGLER T, Moen A, Zhang W, Cox NJ, et al
    Global Influenza Surveillance and Response System: 70 years of responding to the expected and preparing for the unexpected.
    Lancet. 2022;400:981-982.
    PubMed        


    MMWR Morb Mortal Wkly Rep

  21. MCCONEGHY KW, White EM, Blackman C, Santostefano CM, et al
    Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:1235-1238.
    PubMed         Abstract available


    N Engl J Med

  22. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: Assessing Bivalent Vaccines against Covid-19.
    N Engl J Med. 2022;387:e37.
    PubMed        


    PLoS One

  23. GRAVAGNA K, Wolfson C, Sulis G, Buchan SA, et al
    Influenza vaccine coverage and factors associated with non-vaccination among adults at high risk for severe outcomes: An analysis of the Canadian Longitudinal Study on Aging.
    PLoS One. 2022;17:e0275135.
    PubMed         Abstract available

  24. DE BOER J, Saade U, Granjon E, Trouillet-Assant S, et al
    A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects.
    PLoS One. 2022;17:e0274553.
    PubMed         Abstract available

  25. DAS P, Igoe M, Lenhart S, Luong L, et al
    Geographic disparities and determinants of COVID-19 incidence risk in the greater St. Louis Area, Missouri (United States).
    PLoS One. 2022;17:e0274899.
    PubMed         Abstract available

  26. AZAMI M, Nasirkandy MP, Esmaeili Gouvarchin Ghaleh H, Ranjbar R, et al
    COVID-19 vaccine acceptance among pregnant women worldwide: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0272273.
    PubMed         Abstract available

  27. FULLER S, Kazemian S, Algara C, Simmons DJ, et al
    Assessing the effectiveness of COVID-19 vaccine lotteries: A cross-state synthetic control methods approach.
    PLoS One. 2022;17:e0274374.
    PubMed         Abstract available

  28. ABDUL AZIZ NI, Flanders S, Nungsari M
    Social expectations and government incentives in Malaysia's COVID-19 vaccine uptake.
    PLoS One. 2022;17:e0275010.
    PubMed         Abstract available

  29. ALLEN JD, Priebe Rocha L, Rose R, Hoch A, et al
    Intention to obtain a COVID-19 vaccine among Brazilian immigrant women in the U.S.
    PLoS One. 2022;17:e0274912.
    PubMed         Abstract available

  30. NICHOL B, Simonetti V, McCready J, Steen M, et al
    Barriers and facilitators to vaccination for COVID-19, pertussis, and influenza during pregnancy: Protocol for an umbrella review.
    PLoS One. 2022;17:e0275105.
    PubMed         Abstract available

  31. BETOUKE ONGWE ME, Mouwenda YD, Stam KA, Kremsner PG, et al
    Investigation of urinary metabolomics in a phase I hookworm vaccine trial in Gabon.
    PLoS One. 2022;17:e0275013.
    PubMed         Abstract available

  32. YAKUBU AM, Aryee NA, Bonney EY, Kotey EN, et al
    Molecular characterization of haemagglutinin genes of influenza B viruses circulating in Ghana during 2016 and 2017.
    PLoS One. 2022;17:e0271321.
    PubMed         Abstract available

  33. KALIFF M, Lillsunde Larsson G, Helenius G, Karlsson MG, et al
    Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus-positive samples from women over 30 years participating in cervical cancer screening in Orebro, Sweden.
    PLoS One. 2022;17:e0274825.
    PubMed         Abstract available


    Vaccine

  34. ZHU H, Li X, Ren X, Chen H, et al
    Improving cross-protection against influenza virus in mice using a nanoparticle vaccine of mini-HA.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01165.
    PubMed         Abstract available

  35. OHTA M, Kambayashi Y, Mita H, Kuroda T, et al
    Protective efficacy of a reverse genetics-derived inactivated vaccine against equine influenza virus in horses.
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01155.
    PubMed         Abstract available

  36. STOFFEL ST, Colaninno A, Bram R, Schwenkglenks M, et al
    Pneumococcal vaccination among adult risk patient with axial spondyloarthritis in Switzerland: Data from the survey of the ankylosing spondylitis association of Switzerland (SVMB).
    Vaccine. 2022 Sep 26. pii: S0264-410X(22)01164.
    PubMed         Abstract available

  37. KIEFER MK, Mehl R, Rood KM, Germann K, et al
    Association between social vulnerability and COVID-19 vaccination hesitancy and vaccination in pregnant and postpartum individuals.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01152.
    PubMed         Abstract available

  38. GATES DM, Cohen SA, Orr K, Caffrey AR, et al
    Pediatric influenza vaccination rates lower than previous estimates in the United States.
    Vaccine. 2022 Sep 24. pii: S0264-410X(22)01162.
    PubMed         Abstract available

  39. NOMURA Y, Noda K, Oohashi Y, Okuda S, et al
    Proposal for the revision of guidelines for clinical trials of vaccines to prevent infectious diseases in Japan.
    Vaccine. 2022 Sep 24. pii: S0264-410X(22)01144.
    PubMed         Abstract available

  40. DYSON EH, Simpson AJH, Gwyther RJ, Cuthbertson H, et al
    Serological responses to Anthrax Vaccine Precipitated (AVP) increase with time interval between booster doses.
    Vaccine. 2022 Sep 21. pii: S0264-410X(22)01045.
    PubMed         Abstract available

  41. MUES KE, Kirk B, Patel DA, Gelman A, et al
    Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01120.
    PubMed         Abstract available

  42. HABERSAAT KB, Narayan S, Malue Nielsen S, Scherzer M, et al
    How health workers can make a difference in the public COVID-19 vaccination response.
    Vaccine. 2022 Sep 6. pii: S0264-410X(22)01081.
    PubMed        

  43. POLAND GA
    The human immune response to vaccines is symphonic, polyphonic, homophonic, and megaphonic.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01099.
    PubMed        

  44. KUIPER VP, van der Plas P, Hoogerwerf MA, Pieter R Koopman J, et al
    A comparison of two Fendrix hepatitis B vaccination schedules in patients with inflammatory bowel disease.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01100.
    PubMed         Abstract available

  45. NTZIORA F, Georgia Kostaki E, Karapanou A, Mylona M, et al
    Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers.
    Vaccine. 2022 Sep 19. pii: S0264-410X(22)01150.
    PubMed         Abstract available

  46. BANNIETTIS N, Wysocki J, Szenborn L, Phongsamart W, et al
    A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of catch-up vaccination regimens of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants, c
    Vaccine. 2022 Sep 20. pii: S0264-410X(22)01086.
    PubMed         Abstract available

  47. FENG T, Li M, Zhang L, Li S, et al
    Immunity of two novel hepatitis C virus polyepitope vaccines.
    Vaccine. 2022 Sep 20. pii: S0264-410X(22)01115.
    PubMed         Abstract available

  48. RUCKSTUHL L, Czock A, Haile SR, Lang P, et al
    Influence of cantonal health policy frameworks & activities on the influenza vaccination rate in patients with non-communicable diseases in Switzerland.
    Vaccine. 2022 Sep 22. pii: S0264-410X(22)01148.
    PubMed         Abstract available


    Virology

  49. WANG R, Huang X, Cao T, Sun C, et al
    Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants.
    Virology. 2022;576:61-68.
    PubMed         Abstract available


    Virus Res

  50. LUO C, Wang Q, Guo R, Zhang J, et al
    A novel Pseudorabies virus vaccine developed using HDR-CRISPR/Cas9 induces strong humoral and cellular immune response in mice.
    Virus Res. 2022 Sep 26:198937. doi: 10.1016/j.virusres.2022.198937.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: